The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Shatalov P.A.

National Medical Research Center of Radiology of the Ministry of Health of Russia

Raygorodskaya M.P.

National Medical Research Center of Radiology of the Ministry of Health of Russia

Shinkarkina A.P.

National Medical Research Center of Radiology of the Ministry of Health of Russia

Murzaeva A.V.

National Medical Research Center of Radiology of the Ministry of Health of Russia

Makarchuk V.M.

National Medical Research Center of Radiology of the Ministry of Health of Russia

Averinskaya D.A.

National Medical Research Center of Radiology of the Ministry of Health of Russia

Traspov A.A.

National Medical Research Center of Radiology of the Ministry of Health of Russia

Kaprin A.D.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of Ministry of Russia;
Peoples’ Friendship University of Russia

Shegai P.V.

National Medical Research Center of Radiology of the Ministry of Health of Russia

The role of pharmacogenomics in personalized treatment of oncological diseases

Authors:

Shatalov P.A., Raygorodskaya M.P., Shinkarkina A.P., Murzaeva A.V., Makarchuk V.M., Averinskaya D.A., Traspov A.A., Kaprin A.D., Shegai P.V.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2023;12(6): 75‑81

DOI: 10.17116/onkolog20231206175

Read: 1276 times

Download PDF (RU)
Contact the author
Table of contents

THE ROLE OF PHARMACOGENOMICS IN PERSONALIZED TREATMENT OF ONCOLOGICAL DISEASES
THE ROLE OF PHARMACOGENOMICS IN PERSONALIZED TREATMENT OF ONCOLOGICAL DISEASES

To cite this article:

Shatalov PA, Raygorodskaya MP, Shinkarkina AP, et al. . The role of pharmacogenomics in personalized treatment of oncological diseases. P.A. Herzen Journal of Oncology. 2023;12(6):75‑81. (In Russ.)
https://doi.org/10.17116/onkolog20231206175

Подписка 2025-2 (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Mediasphera_Net
Close metadata
Recommended articles:
Tumor models in cancer research. P.A. Herzen Journal of Onco­logy. 2024;(4):72-76
History creates man, and man creates history. On the 125th anni­versary of the P.A. Herzen Moscow Onco­logy Research Institute. P.A. Herzen Journal of Onco­logy. 2024;(6):5-11
Use of a new tetrapeptide analgesic at the stages of anti­tumor therapy. P.A. Herzen Journal of Onco­logy. 2024;(6):23-32
Rela­tionship between pregnancy and the risk of mali­gnant neoplasms of the female reproductive system. Russian Bulletin of Obstetrician-Gynecologist. 2024;(3):48-54
Pharmacogenomic and pharmacometabolomic biomarkers of the effi­cacy and safety of anti­depressants: focus on sele­ctive sero­tonin reuptake inhi­bitors. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):26-35
Biobanking in clinical trials invo­lving multiple scle­rosis patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7-2):7-15
Cost of supportive cancer care in the Russian Fede­ration. Part 1. Medi­cal Technologies. Asse­ssment and Choice. 2024;(3):93-103
Asse­ssment of cyto­kine status in patients with onco­logical diseases and severe COVID-19. Russian Journal of Evidence-Based Gastroenterology. 2024;(3):60-66
Oral cavity cancer epidemiology in men and women in the Sibe­rian Fede­ral District. Russian Journal of Preventive Medi­cine. 2024;(11):46-53
Cost of supportive cancer care in the Russian Fede­ration. Part 2. Medi­cal Technologies. Asse­ssment and Choice. 2024;(4):63-73

Malignant neoplasms have possible specific genetic characteristics that may determine the effectiveness of various treatments. Pharmacogenomics in oncology represents an advanced approach aimed at identifying the genetic features of tumors to select the most optimal therapeutic strategies. This review focuses on the role of pharmacogenomic approaches in the implementation of personalized treatment for oncological diseases. Pharmacogenomics is a cutting-edge field that relies not only on advances in next-generation sequencing but also on modern methods and algorithms for processing large volumes of data. This review discusses the relationship between pharmacogenomics and next-generation sequencing technologies, machine learning, and artificial intelligence. It emphasizes the importance of accumulating real-world data to enable the proper interpretation of identified genetic mutations and the use of this information in treatment personalization. The review also covers existing pharmacogenomic platforms and characterizes a domestically developed pharmacogenomic platform for making clinical decisions in oncology.

Keywords:

pharmacogenomics
personalized treatment
oncology
precision medicine

Authors:

Shatalov P.A.

National Medical Research Center of Radiology of the Ministry of Health of Russia

Raygorodskaya M.P.

National Medical Research Center of Radiology of the Ministry of Health of Russia

Shinkarkina A.P.

National Medical Research Center of Radiology of the Ministry of Health of Russia

Murzaeva A.V.

National Medical Research Center of Radiology of the Ministry of Health of Russia

Makarchuk V.M.

National Medical Research Center of Radiology of the Ministry of Health of Russia

Averinskaya D.A.

National Medical Research Center of Radiology of the Ministry of Health of Russia

Traspov A.A.

National Medical Research Center of Radiology of the Ministry of Health of Russia

Kaprin A.D.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of Ministry of Russia;
Peoples’ Friendship University of Russia

Shegai P.V.

National Medical Research Center of Radiology of the Ministry of Health of Russia

Received:

12.09.2023

Accepted:

28.09.2023

List of references:

  1. Good BM, Ainscough BJ, McMichael JF, Su AI, Griffith OL. Organizing knowledge to enable personalization of medicine in cancer. Genome Biol. 2014;15(8):438.  https://doi.org/10.1186/s13059-014-0438-7
  2. Kotelnikova EA, Pyatnitskiy M, Paleeva A, Kremenetskaya O, Vinogradov D. Practical aspects of NGS-based pathways analysis for personalized cancer science and medicine. Oncotarget. 2016;7(32):52493-52516. https://doi.org/10.18632/oncotarget.9370
  3. Yates LR, Seoane J, Le Tourneau C, Siu LL, Marais R, Michiels S, Soria JC, Campbell P, Normanno N, Scarpa A, et al. The European Society for Medical Oncology (ESMO) precision medicine glossary. Ann Oncol. 2017;29(1):30-35.  https://doi.org/10.1093/annonc/mdx707
  4. Manchanda R, Lieberman S, Gaba F, Lahad A, Levy-Lahad E. Population screening for inherited predisposition to breast and ovarian cancer. Annu Rev Genomics Hum Genet. 2020;21:373-412.  https://doi.org/10.1146/annurev-genom-083118-015253
  5. Kim JH, Yoon S, Lee DH, Jang SJ, Chun SM, Kim SW. Real‐world utility of next‐generation sequencing for targeted gene analysis and its application to treatment in lung adenocarcinoma. Cancer Med. 2021;10(10):3197-3204. https://doi.org/10.1002/cam4.3874
  6. El‐Deiry WS, Goldberg RM, Lenz H, Shields AF, Gibney GT, Tan AR, Brown J, Eisenberg B, Heath EI, Phuphanich S, et al. The current state of molecular testing in the treatment of patients with solid tumors, 2019. CA Cancer J Clin. 2019;69(4):305-343.  https://doi.org/10.3322/caac.21560
  7. Mhandire DZ, Goey AKL. The value of pharmacogenetics to reduce drug-related toxicity in cancer patients. Mol Diagn Ther. 2022;26(2):137-151.  https://doi.org/10.1007/s40291-021-00575-x
  8. Hertz DL, McLeod HL. Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity. J Hum Genet. 2013;58(6):346-352.  https://doi.org/10.1038/jhg.2013.42
  9. Kapoor R, Tan-Koi WC, Teo YY. Role of pharmacogenetics in public health and clinical health care: a SWOT analysis. Eur J Hum Genet. 2016;24(12):1651-1657. https://doi.org/10.1038/ejhg.2016.114
  10. Kamps R, Brandão RD, Bosch BJ, Paulussen AD, Xanthoulea S, Blok MJ, Romano A. Next-generation sequencing in oncology: genetic diagnosis, risk prediction and cancer classification. Int J Mol Sci. 2017;18(2):308.  https://doi.org/10.3390/ijms18020308
  11. Hussen BM, Abdullah ST, Salihi A, Sabir DK, Sidiq KR, Rasul MF, Hidayat HJ, Ghafouri-Fard S, Taheri M, Jamali E. The emerging roles of NGS in clinical oncology and personalized medicine. Pathol Res Pract. 2022;230:153760. https://doi.org/10.1016/j.prp.2022.153760
  12. Doyle MA, Li J, Doig K, Fellowes A, Wong SQ. Studying cancer genomics through next-generation DNA sequencing and bioinformatics. In: Trent R, ed. Clinical bioinformatics. Methods in molecular biology. NY: Humana New York; 2014;83-98.  https://doi.org/10.1007/978-1-4939-0847-9_6
  13. Luthra R, Chen H, Roy-Chowdhuri S, Singh RR. Next-generation sequencing in clinical molecular diagnostics of cancer: advantages and challenges. Cancers (Basel). 2015;7(4):2023-2036. https://doi.org/10.3390/cancers7040874
  14. Purpura CA, Garry EM, Honig N, Case A, Rassen JA. The role of real‐world evidence in FDA‐approved new drug and biologics license applications. Clin Pharmacol Ther. 2022;111(1):135-144.  https://doi.org/10.1002/cpt.2474
  15. Liu B, Morrison CD, Johnson CS, Trump DL, Qin M, Conroy JC, Wang J, Liu S. Computational methods for detecting copy number variations in cancer genome using next generation sequencing: principles and challenges. Oncotarget. 2013;4(11):1868-1881. https://doi.org/10.18632/oncotarget.1537
  16. Liu B, Conroy JM, Morrison C, Odunsi AO, Qin M, Wei L, Trump DL, Johnson CS, Liu S, Wang J. Structural variation discovery in the cancer genome using next generation sequencing: computational solutions and perspectives. Oncotarget. 2015;6(8):5477-5489. https://doi.org/10.18632/oncotarget.3491
  17. Lee SY, Kim YC, Lee KY, Lee SY, Lee SY, Lee MK, Lee JE, Jang SH, Jang TW, Choi CM. Multicenter real‐world data of patients harboring rare mutations other than EGFR or ALK in advanced or metastatic non‐small cell lung cancer. Thorac Cancer. 2022;13(3):380-385.  https://doi.org/10.1111/1759-7714.14266
  18. Zsákai L, Sipos A, Dobos J, Erős D, Szántai-Kis C, Bánhegyi P, Pató J, Őrfi L, Matula Z, Mikala G, et al. Targeted drug combination therapy design based on driver genes. Oncotarget. 2019;10(51):5255-5266. https://doi.org/10.18632/oncotarget.26985
  19. Schwaederle M, Parker BA, Schwab RB, Daniels GA, Piccioni DE, Kesari S, Helsten TL, Bazhenova LA, Romero J, Fanta PT, et al. Precision oncology: the UC San Diego Moores Cancer Center PREDICT Experience. Mol Cancer Ther. 2016;15(4):743-752.  https://doi.org/10.1158/1535-7163.mct-15-0795
  20. Chiu YC, Chen HH, Gorthi A, Mostavi M, Zheng S, Huang Y, Chen Y. Deep learning of pharmacogenomics resources: moving towards precision oncology. Brief Bioinform. 2020;21(6):2066-2083. https://doi.org/10.1093/bib/bbz144
  21. Shegai PV, Shatalov PA, Zabolotneva AA, Falaleeva NA, Ivanov SA, Kaprin AD. Challenges faced by clinicians in the personalized treatment planning: a literature review and the first results of the Russian National Cancer Program. Crit Care Res Pract. 2021;2021:6649771. https://doi.org/10.1155/2021/6649771
  22. Yang Y, Dong X, Xie B, Ding N, Chen J, Li Y, Zhang Q, Qu H, Fang X. Databases and web tools for cancer genomics study. Genomics Proteomics Bioinformatics. 2015;13(1):46-50.  https://doi.org/10.1016/j.gpb.2015.01.005
  23. Khotskaya YB, Mills GB, Mills Shaw KR. Next-generation sequencing and result interpretation in clinical oncology: challenges of personalized cancer therapy. Annu Rev Med. 2017;68:113-125.  https://doi.org/10.1146/annurev-med-102115-021556
  24. Chawla A, Janku F, Wheler JJ, Miller VA, Ryan J, Anhorn R, Zhou Z, Signorovitch J. Estimated cost of anticancer therapy directed by comprehensive genomic profiling in a single-center study. JCO Precis Oncol. 2018;(2):PO.18.00074. https://doi.org/10.1200/PO.18.00074
  25. Davenport T, Kalakota R. The potential for artificial intelligence in healthcare. Future Healthc J. 2019;6(2):94-98.  https://doi.org/10.7861/futurehosp.6-2-94
  26. Jennings LJ, Arcila ME, Corless C, Kamel-Reid S, Lubin IM, Pfeifer J, Temple-Smolkin RL, Voelkerding KV, Nikiforova MN. Guidelines for validation of next-generation sequencing-based oncology panels: a joint consensus recommendation of the Association for Molecular Pathology and College of American Pathologists. J Mol Diagn. 2017;19(3):341-365.  https://doi.org/10.1016/j.jmoldx.2017.01.011
  27. Strom SP. Current practices and guidelines for clinical next-generation sequencing oncology testing. Cancer Biol Med. 2016;13(1):3-11.  https://doi.org/10.28092/j.issn.2095-3941.2016.0004
  28. Carter H, Chen S, Isik L, Tyekucheva S, Velculescu VE, Kinzler KW, Vogelstein B, Karchin R. Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. Cancer Res. 2009;69(16):6660-6667. https://doi.org/10.1158/0008-5472.CAN-09-1133
  29. Milbury CA, Creeden J, Yip WK, Smith DL, Pattani V, Maxwell K, Sawchyn B, Gjoerup O, Meng W, Skoletsky J, et al. Clinical and analytical validation of FoundationOne CDx, a comprehensive genomic profiling assay for solid tumors. PLOS One. 2022;17(3):e0264138. https://doi.org/10.1371/journal.pone.0264138
  30. Moiseev AA, Gur’yanova AA, Suntsova MV, Buzdin AA, Sorokin MI. A case of whole-exome and transcriptome sequencing of tumor for personalized experimental treatment for metastatic mesothelioma. P.A. Herzen Journal of Oncology. 2022;11(2):62-67. (In Russ.). https://doi.org/10.17116/onkolog20221102162
  31. Ginsburg GS, Phillips KA. Precision medicine: from science to value. Health Aff (Millwood). 2018;37(5):694-701.  https://doi.org/10.1377/hlthaff.2017.1624

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.